Table of Contents Author Guidelines Submit a Manuscript
Advances in Virology
Volume 2011, Article ID 260561, 6 pages
http://dx.doi.org/10.1155/2011/260561
Research Article

Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?

WHO Collaborative Centre for AIDS and Sexually Transmitted Disease for EMR, Virology Unit, Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait

Received 20 December 2010; Accepted 25 January 2011

Academic Editor: Jay C. Brown

Copyright © 2011 Nada Madi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. De Clerq, “New inhibitors of human cytomegalovirus (HCMV) on the horizon,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 5, pp. 1079–1083, 2003. View at Publisher · View at Google Scholar · View at PubMed
  2. K. K. Biron, “Antiviral drugs for cytomegalovirus diseases,” Antiviral Research, vol. 71, no. 2-3, pp. 154–163, 2006. View at Publisher · View at Google Scholar · View at PubMed
  3. R. S. Cvetkovic and K. Wellington, “Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients,” Drugs, vol. 65, no. 6, pp. 859–878, 2005. View at Publisher · View at Google Scholar
  4. S. S. Kanj, A. I. Sharara, P. A. Clavien, and J. D. Hamilton, “Cytomegalovirus infection following liver transplantation: review of the literature,” Clinical Infectious Diseases, vol. 22, no. 3, pp. 537–549, 1996. View at Google Scholar
  5. A. P. Limaye, L. Corey, D. M. Koelle, C. L. Davis, and M. Boeckh, “Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants,” Lancet, vol. 356, no. 9230, pp. 645–649, 2000. View at Google Scholar
  6. K. L. Springer, S. Chou, S. Li et al., “How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients,” Journal of Clinical Microbiology, vol. 43, no. 1, pp. 208–213, 2005. View at Publisher · View at Google Scholar · View at PubMed
  7. N. Madi, W. Al-Nakib, A. S. Mustafa, T. Saeed, A. Pacsa, and M. R. N. Nampoory, “Detection and monitoring of cytomegalovirus infection in renal transplant patients by quantitative real-time PCR,” Medical Principles and Practice, vol. 16, no. 4, pp. 268–273, 2007. View at Publisher · View at Google Scholar · View at PubMed
  8. S. Chou, A. Erice, M. C. Jordan et al., “Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance,” Journal of Infectious Diseases, vol. 171, no. 3, pp. 576–583, 1995. View at Google Scholar
  9. A. Erice, “Resistance of human cytomegalovirus to antiviral drugs,” Clinical Microbiology Reviews, vol. 12, no. 2, pp. 286–297, 1999. View at Google Scholar
  10. G. Boivin, N. Goyette, H. Rollag et al., “Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir,” Antiviral Therapy, vol. 14, no. 5, pp. 697–704, 2009. View at Google Scholar
  11. S. Chou, N. S. Lurain, K. D. Thompson, R. C. Miner, and W. L. Drew, “Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus,” Journal of Infectious Diseases, vol. 188, no. 1, pp. 32–39, 2003. View at Publisher · View at Google Scholar · View at PubMed
  12. N. S. Lurain, A. Weinberg, C. S. Crumpacker, and S. Chou, “Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 10, pp. 2775–2780, 2001. View at Publisher · View at Google Scholar · View at PubMed
  13. C. Gilbert, J. Bestman-Smith, and G. Boivin, “Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms,” Drug Resistance Updates, vol. 5, no. 2, pp. 88–114, 2002. View at Publisher · View at Google Scholar
  14. S. Hantz, F. Garnier-Geoffroy, M.-C. Mazeron et al., “Drug-resistant cytomegalovirus in transplant recipients: a French cohort study,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 12, pp. 2628–2640, 2010. View at Publisher · View at Google Scholar · View at PubMed
  15. V. C. Emery, “Investigation of CMV disease in immunocompromised patients,” Journal of Clinical Pathology, vol. 54, no. 2, pp. 84–88, 2001. View at Publisher · View at Google Scholar
  16. V. C. Emery, A. F. Hassan-Walker, A. K. Burroughs, and P. D. Griffiths, “Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts,” Journal of Infectious Diseases, vol. 185, no. 12, pp. 1723–1728, 2002. View at Publisher · View at Google Scholar · View at PubMed
  17. M. T. Van Der Beek, S. P. Berger, A. C. T. M. Vossen et al., “Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance,” Transplantation, vol. 89, no. 3, pp. 320–326, 2010. View at Publisher · View at Google Scholar · View at PubMed
  18. A. Humar, D. Kumar, G. Boivin, and A. M. Caliendo, “Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease,” Journal of Infectious Diseases, vol. 186, no. 6, pp. 829–833, 2002. View at Publisher · View at Google Scholar · View at PubMed
  19. A. P. Limaye, “Ganciclovir-resistant cytomegalovirus in organ transplant recipients,” Clinical Infectious Diseases, vol. 35, no. 7, pp. 866–872, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus